利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.024 秒)

    Method for monitoring the effectiveness of teracycline in the treatment of asthma
    2.
    发明申请
    Method for monitoring the effectiveness of teracycline in the treatment of asthma 审中-公开
    监测万古霉素治疗哮喘有效性的方法

    公开(公告)号：US20060128675A1

    公开(公告)日：2006-06-15

    申请号：US10523856

    申请日：2003-08-08

    申请人： Helen Durkin ,  Rauno Joks ,  Tamar Smith-Norowitz ,  Martin Bluth

    发明人： Helen Durkin ,  Rauno Joks ,  Tamar Smith-Norowitz ,  Martin Bluth

    IPC分类号： A61K31/65

    CPC分类号： G01N33/6854 ,  A61K31/65 ,  G01N2800/122 ,  G01N2800/52 ,  A61K2300/00

    摘要： The present invention is directed to a method of lowering excess IgE levels in a mammal suffering from a disease where IgE is pathogenic which method comprises administering to said mammal an IgE lowering effective amount of a tetracycline such as minocycline or doxycline. It is also directed to a method of monitoring the effectiveness of a drug in lowering the concentration of excess IgE in plasma in a mammal suffering from the disease in which IgE is pathogenic which method comprises making a first determination of the concentration of IgE in the plasma of said mammal at an initial time; administering to said mammal the drug; making a second determination of the concentration of IgE in the plasma of said mammal after the initial time and after administration of the drug and comparing the values obtained from the first and second determinations, such that if the value of the second determination is higher than or about the same as the value of the first determination and above a threshold level, then the dosage amount of the drug administered to the mammal is increased; otherwise the dosage amount is maintained.

    摘要翻译： 本发明涉及一种降低患有IgE致病性疾病的哺乳动物中过量IgE水平的方法，该方法包括向所述哺乳动物施用降低有效量的四环素如米诺环素或多西环素的IgE。 还涉及一种监测药物在降低IgE致病性疾病的哺乳动物中血浆中过量IgE浓度降低的有效性的方法，该方法包括首先测定血浆中IgE的浓度 的哺乳动物; 向所述哺乳动物施用所述药物; 在所述哺乳动物的初始时间和给药后第二次测定所述哺乳动物血浆中IgE的浓度，并比较从第一次和第二次测定得到的值，使得如果第二次测定的值高于或 与第一次测定的值相同且高于阈值水平，则给予哺乳动物的药物的给药量增加; 否则维持剂量。

    Purified Ethyl Ester Sophorolipid for the Treatment of Sepsis
    4.
    发明申请
    Purified Ethyl Ester Sophorolipid for the Treatment of Sepsis 审中-公开
    纯化乙酯苦参碱治疗脓毒症

    公开(公告)号：US20120142621A1

    公开(公告)日：2012-06-07

    申请号：US13196014

    申请日：2011-08-02

    申请人： George Falus ,  Maja Nowakowski ,  Martin Bluth ,  John Aikens

    发明人： George Falus ,  Maja Nowakowski ,  Martin Bluth ,  John Aikens

    IPC分类号： A61K31/7048 ,  A61P31/00 ,  C12P19/62

    CPC分类号： A61K31/7028 ,  C12P19/44 ,  C12P19/62

    摘要： A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by Candida species, for treating and preventing sepsis/septic shock. The method of producing sophorolipids is through microbial resting cells of Candida bombicola. The sophorolipids obtained from resting state cultures are isolated as a complex mixture of compounds and then decanted as a dense oil from the culture broth, subsequently washed to remove free fatty acids. Secondary chemical transformation via base catalyzed hydrolysis is used to reduce the 8 possible structural sophorolipid species to a single moiety, the 17-L-[(2′-O-b-D-glucopyranosyl-b-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de-acetylated free acid. The compound acts primarily through decreasing inflammatory cytokines and eliciting other synergistic anti-inflammatory mechanisms by blocking TLR4-CD14 upstream of the inflammatory signaling cascade. The compound can be administered either intraperitoneally or intravenously at single or multiple doses of 5-30 mg/kg of weight in solvent media or in capped nanoparticles, preferably within 48 hours of sepsis inception.

    摘要翻译： 一种没有由念珠菌种类产生的乙酰化基团的微生物乙酸酯槐糖衍生物，用于治疗和预防败血症/败血性休克。 生产槐糖脂的方法是通过假丝酵母（Candida bombicola）的微生物静息细胞。 从休眠状态培养物获得的槐油脂作为化合物的复合混合物分离，然后从培养液中以浓稠的油状物倾析，随后洗涤以除去游离脂肪酸。 17-L - [（2'-ObD-吡喃葡萄糖基-bD-吡喃葡萄糖基） - 氧基] - 顺式-9-十八碳烯酸酯de的单一部分使用通过碱催化水解的二次化学转化将8种可能的结构性槐糖脂类物质 乙酰化游离酸。 该化合物主要通过减少炎症细胞因子起作用，并通过阻断炎症信号传导级联上游的TLR4-CD14引起其他协同抗炎机制。 该化合物可以在溶剂介质或加盖纳米颗粒中以5-30mg / kg重量的单剂量或多次剂量腹膜内或静脉内施用，优选在败血症开始48小时内。